Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Nivolumab in Metastatic Solid Cancers with DNA Damage Repair Alterations
KCT0003722Phase 2
Key facts
- Status
- Completed
- Start
- Jun 2019
- Countries
- 1
- Sponsor
- Ministry of Health & Welfare
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Drugs
- nivolumab
- Conditions
- Non-hematologic malignancy
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Non-hematologic malignancy, sponsored by Ministry of Health & Welfare. Started Jun 2019; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Nivolumab monotherapy
Single-group arm in which all enrolled patients receive nivolumab alone for treatment of metastatic solid tumors with DNA damage repair/response alterations.
03
Who it enrols
Adult patients with metastatic solid tumors that harbor genetic alterations in DNA damage repair and response pathways and have radiographic or clinical progression after standard treatments.
Beyond the preview
Go deeper on KCT0003722.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003722.